Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2]

See also

References

  1. ^ US 10676465, Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", issued 9 June 2020, assigned to Pfizer Inc 
  2. ^ Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.
Allikas: http://en.wikipedia.org/wiki/Lotiglipron
No tags for this post.